These innovative compounds represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose https://kiararzdr779388.boyblogguide.com/37907094/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide